focus -WSS

focus

author：explore 2025-10-02 18:48:02 - browse：6426

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Texas Medical Board asked to define abortion emergency exception

WSS

Why Novartis is going to walk from its acquisition of MorphoSys

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Johnson & Johnson sued for allegedly overpaying for workers' drugs

A protest over insulin prices is seen as a fight for life

Unique patient identifier: Experts argue the benefits, pitfalls

Dementia risk linked to living in disadvantaged areas: Study

hotspot

focus

hotspot

Alkermes shareholders re

Mystery swirls around US soldier who entered North Korea days ago, officials say

Peter Hotez and the public health issue of online harassment

Sanders wants to replace patents with prizes for drug inventions

Drug repurposing or repositioning? The language matters

The Biogen Aduhelm mess could happen again

How one medical school became remarkably diverse

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Drug repurposing or repositioning? The language matters

The Biogen Aduhelm mess could happen again

focus

The stock market has soared this year, but will it last? Experts weigh in

US jobless claims fall again as labor market continues to flash strength

Texas Medical Board asked to define abortion emergency exception

There’s a way to spot data fakery. All journals should be using it

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Sanders wants to replace patents with prizes for drug inventions

knowledge

knowledge

hotspot

hotspot